Cargando…

Propensity score adjusted comparison of three-factor versus four-factor prothrombin complex concentrate for emergent warfarin reversal: a retrospective cohort study

BACKGROUND: Prothrombin Complex Concentrates (PCC) are prescribed for emergent warfarin reversal (EWR). The comparative effectiveness and safety among PCC products are not fully understood. METHODS: Patients in an academic level one trauma center who received PCC3 or PCC4 for EWR were identified. Pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Margraf, David J., Seaburg, Scott, Beilman, Gregory J., Wolfson, Julian, Gipson, Jonathan C., Chapman, Scott A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691107/ https://www.ncbi.nlm.nih.gov/pubmed/33243152 http://dx.doi.org/10.1186/s12873-020-00386-z

Ejemplares similares

Comparison of 3-factor versus 4-factor prothrombin complex concentrate for emergent warfarin reversal: a systematic review and meta-analysis
por: Margraf, David J., et al.
Publicado: (2022)

Three- versus four-factor prothrombin complex concentrate for the reversal of warfarin-induced bleeding
por: Holt, Tara, et al.
Publicado: (2018)

Comparison of 3-Factor Prothrombin Complex Concentrate and Low-Dose Recombinant Factor VIIa for Warfarin Reversal
por: Chapman, Scott A, et al.
Publicado: (2014)

Prothrombin complex concentrates in warfarin anticoagulation reversal
por: Costa-Lima, Carolina, et al.
Publicado: (2012)

Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding
por: Rech, Megan A., et al.
Publicado: (2021)

Evaluation of fixed dose four-factor prothrombin complex concentrate for warfarin reversal at a level 1 trauma center
por: Drone, H, et al.
Publicado: (2015)

Four-factor prothrombin complex concentrate (Beriplex® P/N) is superior to three-factor prothrombin complex concentrate for reversal of coumarin anticoagulation
por: Herzog, E, et al.
Publicado: (2015)

Prothrombin Complex Concentrate for Rapid Reversal of Warfarin Anticoagulation to Allow Neuraxial Blockade
por: Skerritt, Conor, et al.
Publicado: (2014)

Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy
por: Wójcik, Cezary, et al.
Publicado: (2009)

Warfarin Reversal With Four-Factor Prothrombin Complex Concentrate for Left Ventricular Assist Device Conversion Surgery Monitored by TEG6s: A Case Report
por: Ito, Hisakatsu, et al.
Publicado: (2022)

Reversibility of Apixaban Anticoagulation with a Four‐Factor Prothrombin Complex Concentrate in Healthy Volunteers
por: Nagalla, S, et al.
Publicado: (2016)

Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis
por: Costa, Olivia S., et al.
Publicado: (2022)

Thromboembolic Risk of 4-Factor Prothrombin Complex Concentrate versus Fresh Frozen Plasma for Urgent Warfarin Reversal in the Emergency Department
por: Maguire, Michelle, et al.
Publicado: (2019)

Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding
por: Go, Alan S., et al.
Publicado: (2022)

Factors contributing to poor outcome in patients on warfarin receiving 4-factor prothrombin complex concentrate in critically ill
por: Mishra, Ajay Kumar, et al.
Publicado: (2021)

Reversal of edoxaban-induced anticoagulation by the four-factor prothrombin complex concentrate Beriplex(® )in a rabbit model
por: Herzog, E, et al.
Publicado: (2014)

Four‐factor prothrombin complex concentrate reverses apixaban‐associated bleeding in a rabbit model of acute hemorrhage
por: Herzog, E., et al.
Publicado: (2015)

Use of prothrombin complex concentrate in warfarin anticoagulation reversal in the emergency department: a quality improvement study of administration delays
por: Bordeleau, Simon, et al.
Publicado: (2015)

A Rare Case of Skin Necrosis Following Extravasation of Prothrombin Complex Concentrate (PCC) Infusion During Warfarin Reversal
por: Smith, Emma C, et al.
Publicado: (2023)

Increased risk of volume overload with plasma compared with four‐factor prothrombin complex concentrate for urgent vitamin K antagonist reversal
por: Refaai, Majed A., et al.
Publicado: (2015)

Four-factor prothrombin complex concentrate (Beriplex® P/N) mediated reversal of apixaban-induced bleeding in a rabbit model
por: Herzog, E, et al.
Publicado: (2015)

Reduced Time to Procedure for Gastrointestinal Bleeding After Warfarin Reversal With Four-Factor Complex Concentrate as Compared to Plasma
por: Spector, Hannah, et al.
Publicado: (2023)

Reversal of oral anticoagulation with prothrombin complex concentrate (Octaplex)
por: Riess, H, et al.
Publicado: (2007)

Clinical utilization of four-factor prothrombin complex concentrate: a retrospective single center study
por: Naeem, Zaina, et al.
Publicado: (2021)

Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors
por: Tao, Jing, et al.
Publicado: (2018)

Reversing direct factor Xa or thrombin inhibitors: Factor V addition to prothrombin complex concentrate is beneficial in vitro
por: Brinkman, Herm Jan M., et al.
Publicado: (2022)

Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Bleeding in Neurosurgical Patients: A Single-Center Experience
por: Mačiukaitienė, Jomantė, et al.
Publicado: (2018)

The role of prothrombin complex concentrates in reversal of target specific anticoagulants
por: Babilonia, Katrina, et al.
Publicado: (2014)

Clinical factors influencing normalization of prothrombin time after stopping warfarin: a retrospective cohort study
por: Schulman, Sam, et al.
Publicado: (2008)

Evaluation of the prothrombotic potential of four-factor prothrombin complex concentrate (4F-PCC) in animal models
por: Ghosh, Subhajit, et al.
Publicado: (2021)

Erratum to “Clinical utilization of four-factor prothrombin complex concentrate: a retrospective single center study”
Publicado: (2023)

Optimal Dosage and Administration Practices for Vitamin K Antagonist Reversal With 4-Factor Prothrombin Complex Concentrate
por: Rhoney, Denise H., et al.
Publicado: (2020)

Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation
por: Lu, Genmin, et al.
Publicado: (2020)

Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial
por: Schenk, Bettina, et al.
Publicado: (2018)

Acquired deficiency of prothrombin complex coagulation factors in major bleeding is a therapeutic indication of 4‐factor prothrombin complex concentrates
por: Wiedermann, Christian J.
Publicado: (2020)

Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding
por: Stevens, Victoria M., et al.
Publicado: (2021)

Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation
por: Grottke, Oliver, et al.
Publicado: (2016)

Safety of a Four‐factor Prothrombin Complex Concentrate Versus Plasma for Vitamin K Antagonist Reversal: An Integrated Analysis of Two Phase IIIb Clinical Trials
por: Milling, Truman J., et al.
Publicado: (2016)

Impact of a Pharmacist-Driven Prothrombin Complex Concentrate Protocol on Time to Administration in Patients with Warfarin-associated Intracranial Hemorrhage
por: Corio, Jessica L., et al.
Publicado: (2018)

Use of four‐factor prothrombin complex concentrate for the mitigation of rivaroxaban‐induced bleeding in an emergent coronary artery bypass graft
por: Liu, Michael, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hb1189kuv3l0obk1ihtrdi1fo2